Dr. David Allen Holmes, AU.D. Audiologist Medicare: Accepting Medicare Assignments Practice Location: 1125 W Iron Springs Rd, Prescott, AZ 86305 Phone: 928-778-5132 |
Dr. Robert Paul Drew, AU.D., M.S., CCC Audiologist - Assistive Technology Supplier Medicare: Not Enrolled in Medicare Practice Location: 2136 Santa Fe Spgs, Prescott, AZ 86305 Phone: 928-713-7295 |
Clear Choice Leasing Audiologist Medicare: Not Enrolled in Medicare Practice Location: 8 Wildwood Dr, Prescott, AZ 86305 Phone: 928-581-3036 |
Ms. Evelyn Louise Gong, AU.D. Audiologist Medicare: Not Enrolled in Medicare Practice Location: 500 Highway 89 North, Prescott, AZ 86313 Phone: 928-445-4860 |
News Archive
In a study of older women, the prevalence of stress- and urgency urinary incontinence (SUI and UUI) was at least two-fold higher among women in the highest category of body mass index (BMI) or fat mass compared with women in the lowest category.
Cancer Research UK scientists have created the first 3D structure of a key protein that protects against the development of cancer, according to research published in Nature Structural & Molecular Biology today.
Almost four years after the Medicare Part D prescription drug program went into effect, an overwhelming majority (88 percent) of America's seniors approve of their individual plan and coverage. In a national survey released this morning by the nonpartisan Medicare Today Coalition, 95 percent of seniors who used their plan and received prescriptions over the past year also reported that their plan has worked well, while 85 percent continue to find their monthly premium to be affordable.
Norgen Biotek Corp., an innovative privately held Canadian biotechnology company focusing primarily on advancing powerful tools for nucleic acids (NA) and protein purification, today announced the launch of 6 novel kits for the fast and simple isolation of NA from blood, plasma/serum and urine, including cell-free-circulating (cfc)RNA, cfcDNA and sequential cfcDNA and cfcRNA.
Aastrom Biosciences, Inc., a leading developer of expanded autologous cellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that it has priced a public offering of 10,000,000 units, with each unit consisting of one share of the Company's common stock and one warrant to purchase one share of common stock, at a purchase price of $2.25 per unit for an aggregate offering amount of $22.5 million.
› Verified 6 days ago